Health Economics›Breast cancer›Metastatic or unresectable disease subsequent lines

Metastatic or unresectable disease subsequent lines

Breast cancer · 30 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 27 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel, Pertuzumab, Trastuzumab Variant #01	ERBB2	R 108 032	21d	5.3 mo	32.5 mo	8	R 864 257 PFS proxy	2
Paclitaxel, Pertuzumab, Trastuzumab emtansine Variant #01	ERBB2	R 107 144	21d	—	—	—	—	—
EHP Variant #01	ERBB2	R 98 755	21d	5.3 mo	32.5 mo	8	R 790 039 PFS proxy	2
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	15.5 mo	23.4 mo	23	R 1 863 446 PFS proxy	9
THP (Docetaxel) Variant #01	ERBB2	R 78 650	21d	5.3 mo	32.5 mo	8	R 629 202 PFS proxy	2
GHP Variant #01	ERBB2	R 77 354	21d	5.3 mo	32.5 mo	8	R 618 833 PFS proxy	2
THP (Paclitaxel) Variant #01	ERBB2	R 76 176	21d	5.3 mo	32.5 mo	8	R 609 410 PFS proxy	2
XHP Variant #01	ERBB2	R 75 498	21d	8.2 mo	32.5 mo	12	R 905 975 PFS proxy	3
VHP Variant #01	ERBB2	R 74 998	21d	5.3 mo	32.5 mo	8	R 599 981 PFS proxy	2
Pertuzumab and Trastuzumab Variant #02	ERBB2	R 74 512	21d	—	—	—	—	—
nab-Paclitaxel and Trastuzumab Variant #01	ERBB2	R 70 557	28d	4.2 mo	25.0 mo	5	R 352 785 PFS proxy	2
Capecitabine and Neratinib Variant #01	ERBB2	R 58 758	21d	8.8 mo	—	13	R 763 851 PFS proxy	1
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	7.3 mo	29.9 mo	11	R 455 454 PFS proxy	5
Lapatinib and Trastuzumab Variant #02	ERBB2	R 38 538	28d	2.6 mo	14.0 mo	3	R 115 613 PFS proxy	2
Lapatinib monotherapy Variant #01	ERBB2	R 37 677	28d	1.9 mo	9.5 mo	3	R 113 031 PFS proxy	2
Eribulin and Trastuzumab Variant #01	ERBB2	R 34 681	21d	4.9 mo	23.4 mo	8	R 277 447 PFS proxy	5
Capecitabine and Lapatinib Variant #01	ERBB2	R 24 534	21d	6.8 mo	21.6 mo	10	R 245 345 PFS proxy	7
Eribulin and Margetuximab Variant #01 Partial	ERBB2	R 24 243	21d	6.0 mo	21.6 mo	9	R 218 190 PFS proxy	2
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 16 575	21d	4.2 mo	25.0 mo	7	R 116 028 PFS proxy	2
Vinorelbine and Trastuzumab (VH) Variant #01	ERBB2	R 14 392	28d	5.0 mo	23.4 mo	6	R 86 352 PFS proxy	7
Gemcitabine and Trastuzumab Variant #01	ERBB2	R 13 849	21d	4.6 mo	23.4 mo	7	R 96 940 PFS proxy	4
Docetaxel and Trastuzumab (TH) Variant #01	ERBB2	R 12 507	21d	4.2 mo	25.0 mo	7	R 87 549 PFS proxy	2
Capecitabine and Trastuzumab (XH) Variant #02	ERBB2	R 11 671	21d	5.0 mo	22.7 mo	8	R 93 364 PFS proxy	8
Capecitabine and Trastuzumab (XH) and Tucatinib Variant #01 Partial	ERBB2	R 11 424	21d	7.6 mo	23.3 mo	12	R 137 087 PFS proxy	3
Trastuzumab monotherapy Variant #04	ERBB2	R 10 438	21d	—	—	—	—	2
Vinorelbine and Trastuzumab (VH) and Everolimus Variant #01	ERBB2	R 7 011	7d	7.0 mo	—	31	R 217 349 PFS proxy	1
Gemcitabine and Margetuximab Variant #01 Partial	ERBB2	R 2 843	21d	6.0 mo	21.6 mo	9	R 25 583 PFS proxy	2
Capecitabine and Margetuximab Variant #01 Partial	ERBB2	R 986	21d	6.0 mo	21.6 mo	9	R 8 877 PFS proxy	2
Capecitabine and Pyrotinib Variant #01 Partial	ERBB2	R 986	21d	12.5 mo	—	19	R 18 741 PFS proxy	1
Vinorelbine and Margetuximab Variant #01 Partial	ERBB2	R 486	21d	6.0 mo	21.6 mo	9	R 4 375 PFS proxy	2

30 of 30 regimens shown